论文部分内容阅读
目的系统评价FOXM1表达与非小细胞肺癌(NSCLC)患者临床病理特征及预后的相关性。方法计算机检索PubMed、EMbase、The Cochrane Library(2016年1期),CNKI、WanFang Data和CBM数据库,搜索关于FOXM1表达与NSCLC预后相关性的队列研究,检索时限均为从建库至2016年5月30日。由2位评价员独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用Rev Man 5.3软件进行Meta分析。结果共纳入8个队列研究,共781例患者。Meta分析结果显示:FOXM1在肿瘤Ⅲ~Ⅳ分期的表达明显高于Ⅰ~Ⅱ分期[OR=2.24,95%CI(1.25,4.01),P=0.007],其差异有统计学意义。FOXM1高表达组患者的总生存期[HR=1.77,95%CI(1.42,2.22),P<0.000 01]和无病生存期[HR=1.96,95%CI(1.04,3.17),P=0.04]明显短于低表达组,其差异有统计学意义。结论现有证据表明,FOXM1表达与NSCLC的分期密切有关,且对患者的预后具有预测价值。受纳入研究的数量和质量限制,上述结论尚需开展更多高质量研究予以验证。
Objective To evaluate the relationship between FOXM1 expression and clinicopathological characteristics and prognosis in patients with non-small cell lung cancer (NSCLC). Methods We searched PubMed, EMbase, The Cochrane Library (2016 1), CNKI, WanFang Data and CBM database to search the cohort study on the correlation between FOXM1 expression and prognosis of NSCLC. The search time ranged from database construction to May 2016 30 days. After two reviewers independently screened the literature, extracted data, and assessed the risk of being included in the study, Meta-analysis was performed using Rev Man 5.3 software. Results A total of 8 cohort studies were included, with a total of 781 patients. Meta analysis showed that the expression of FOXM1 in stage Ⅲ ~ Ⅳ was significantly higher than that in stage Ⅰ ~ Ⅱ [OR = 2.24,95% CI (1.25, 4.01, P = 0.007], and the difference was statistically significant. The overall survival was significantly higher in patients with FOXM1 overexpression (HR = 1.77,95% CI 1.42,2.22, P <0.000 01) and disease-free survival (HR = 1.96,95% CI 1.04,3.17) ] Was significantly shorter than the low expression group, the difference was statistically significant. Conclusion The available evidence shows that FOXM1 expression is closely related to the stage of NSCLC and has a predictive value for the prognosis of patients. Due to the quantity and quality limitations of the studies included, the above conclusion still needs to be verified by more high-quality research.